639 related articles for article (PubMed ID: 33257471)
1. Hepatic Krüppel-like factor 16 (KLF16) targets PPARα to improve steatohepatitis and insulin resistance.
Sun N; Shen C; Zhang L; Wu X; Yu Y; Yang X; Yang C; Zhong C; Gao Z; Miao W; Yang Z; Gao W; Hu L; Williams K; Liu C; Chang Y; Gao Y
Gut; 2021 Nov; 70(11):2183-2195. PubMed ID: 33257471
[TBL] [Abstract][Full Text] [Related]
2. Hepatic Krüppel-like factor 14 regulates lipid metabolism in nonalcoholic steatohepatitis mice.
Chen X; Shi W; Xie Y; Wang Y; Yao Q; Ke H; Xu X; Liu H; Liu P; Zhou X
FASEB J; 2023 Aug; 37(8):e23070. PubMed ID: 37389939
[TBL] [Abstract][Full Text] [Related]
3. Resveratrol protects against nonalcoholic fatty liver disease by improving lipid metabolism and redox homeostasis via the PPARα pathway.
Huang Y; Lang H; Chen K; Zhang Y; Gao Y; Ran L; Yi L; Mi M; Zhang Q
Appl Physiol Nutr Metab; 2020 Mar; 45(3):227-239. PubMed ID: 31173696
[TBL] [Abstract][Full Text] [Related]
4. Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD.
Montagner A; Polizzi A; Fouché E; Ducheix S; Lippi Y; Lasserre F; Barquissau V; Régnier M; Lukowicz C; Benhamed F; Iroz A; Bertrand-Michel J; Al Saati T; Cano P; Mselli-Lakhal L; Mithieux G; Rajas F; Lagarrigue S; Pineau T; Loiseau N; Postic C; Langin D; Wahli W; Guillou H
Gut; 2016 Jul; 65(7):1202-14. PubMed ID: 26838599
[TBL] [Abstract][Full Text] [Related]
5. Mindin/Spondin 2 inhibits hepatic steatosis, insulin resistance, and obesity via interaction with peroxisome proliferator-activated receptor α in mice.
Zhu LH; Wang A; Luo P; Wang X; Jiang DS; Deng W; Zhang X; Wang T; Liu Y; Gao L; Zhang S; Zhang X; Zhang J; Li H
J Hepatol; 2014 May; 60(5):1046-54. PubMed ID: 24445216
[TBL] [Abstract][Full Text] [Related]
6. Post-transcriptional activation of PPAR alpha by KLF6 in hepatic steatosis.
Bechmann LP; Vetter D; Ishida J; Hannivoort RA; Lang UE; Kocabayoglu P; Fiel MI; Muñoz U; Patman GL; Ge F; Yakar S; Li X; Agius L; Lee YM; Zhang W; Hui KY; Televantou D; Schwartz GJ; LeRoith D; Berk PD; Nagai R; Suzuki T; Reeves HL; Friedman SL
J Hepatol; 2013 May; 58(5):1000-6. PubMed ID: 23353867
[TBL] [Abstract][Full Text] [Related]
7. Co-option of PPARα in the regulation of lipogenesis and fatty acid oxidation in CLA-induced hepatic steatosis.
Cai D; Li Y; Zhang K; Zhou B; Guo F; Holm L; Liu HY
J Cell Physiol; 2021 Jun; 236(6):4387-4402. PubMed ID: 33184849
[TBL] [Abstract][Full Text] [Related]
8. PARP1-mediated PPARα poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease.
Huang K; Du M; Tan X; Yang L; Li X; Jiang Y; Wang C; Zhang F; Zhu F; Cheng M; Yang Q; Yu L; Wang L; Huang D; Huang K
J Hepatol; 2017 May; 66(5):962-977. PubMed ID: 27979751
[TBL] [Abstract][Full Text] [Related]
9. CD38 Deficiency Protects Mice from High Fat Diet-Induced Nonalcoholic Fatty Liver Disease through Activating NAD
Xie L; Wen K; Li Q; Huang CC; Zhao JL; Zhao QH; Xiao YF; Guan XH; Qian YS; Gan L; Wang LF; Deng KY; Xin HB
Int J Biol Sci; 2021; 17(15):4305-4315. PubMed ID: 34803499
[TBL] [Abstract][Full Text] [Related]
10. Pdcd4 promotes lipid deposition by attenuating PPARα-mediated fatty acid oxidation in hepatocytes.
Du X; Osoro EK; Chen Q; Yan X; Gao D; Wu L; Ren J; Feng L; Wu N; Lu K; Yang X; Zhong B; Han Y; Zhang F; Li D; Lan X; Lu S
Mol Cell Endocrinol; 2022 Apr; 545():111562. PubMed ID: 35051553
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of miR-181a impairs lipid metabolism by targeting PPARα expression in nonalcoholic fatty liver disease.
Huang R; Duan X; Liu X; Cao H; Wang Y; Fan J; Wang B
Biochem Biophys Res Commun; 2019 Jan; 508(4):1252-1258. PubMed ID: 30558790
[TBL] [Abstract][Full Text] [Related]
12. Phytochemical gallic acid alleviates nonalcoholic fatty liver disease via AMPK-ACC-PPARa axis through dual regulation of lipid metabolism and mitochondrial function.
Zhang J; Zhang W; Yang L; Zhao W; Liu Z; Wang E; Wang J
Phytomedicine; 2023 Jan; 109():154589. PubMed ID: 36610145
[TBL] [Abstract][Full Text] [Related]
13. α-Lactalbumin Peptide Asp-Gln-Trp Ameliorates Hepatic Steatosis and Oxidative Stress in Free Fatty Acids-Treated HepG2 Cells and High-Fat Diet-Induced NAFLD Mice by Activating the PPARα Pathway.
Chen H; Ma Y; Qi X; Tian J; Ma Y; Niu T
Mol Nutr Food Res; 2023 Aug; 67(16):e2200499. PubMed ID: 37354055
[TBL] [Abstract][Full Text] [Related]
14. PPARα is one of the key targets for dendrobine to improve hepatic steatosis in NAFLD.
Xu Y; Wang M; Luo Y; Liu H; Ling H; He Y; Lu Y
J Ethnopharmacol; 2024 Apr; 323():117684. PubMed ID: 38171466
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D receptor targets hepatocyte nuclear factor 4α and mediates protective effects of vitamin D in nonalcoholic fatty liver disease.
Zhang H; Shen Z; Lin Y; Zhang J; Zhang Y; Liu P; Zeng H; Yu M; Chen X; Ning L; Mao X; Cen L; Yu C; Xu C
J Biol Chem; 2020 Mar; 295(12):3891-3905. PubMed ID: 32051143
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of hepatic CLOCK by PPARα is involved in inhibition of NAFLD.
Luo J; Yan Z; Dai M; Xu L; Zhang H; Xi Y; Yang J; Liu A
J Mol Med (Berl); 2023 Feb; 101(1-2):139-149. PubMed ID: 36527474
[TBL] [Abstract][Full Text] [Related]
17. Ubiquitin-Specific Peptidase 10 (USP10) Inhibits Hepatic Steatosis, Insulin Resistance, and Inflammation Through Sirt6.
Luo P; Qin C; Zhu L; Fang C; Zhang Y; Zhang H; Pei F; Tian S; Zhu XY; Gong J; Mao Q; Xiao C; Su Y; Zheng H; Xu T; Lu J; Zhang J
Hepatology; 2018 Nov; 68(5):1786-1803. PubMed ID: 29698567
[TBL] [Abstract][Full Text] [Related]
18. Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway.
Shen C; Pan Z; Wu S; Zheng M; Zhong C; Xin X; Lan S; Zhu Z; Liu M; Wu H; Huang Q; Zhang J; Liu Z; Si Y; Tu H; Deng Z; Yu Y; Liu H; Zhong Y; Guo J; Cai J; Xian S
J Ethnopharmacol; 2021 Oct; 279():114340. PubMed ID: 34171397
[TBL] [Abstract][Full Text] [Related]
19. Chaperonin counteracts diet-induced non-alcoholic fatty liver disease by aiding sirtuin 3 in the control of fatty acid oxidation.
Weng SW; Wu JC; Shen FC; Chang YH; Su YJ; Lian WS; Tai MH; Su CH; Chuang JH; Lin TK; Liou CW; Chu TH; Kao YH; Wang FS; Wang PW
Diabetologia; 2023 May; 66(5):913-930. PubMed ID: 36692509
[TBL] [Abstract][Full Text] [Related]
20. Icaritin ameliorates hepatic steatosis via promoting fatty acid β-oxidation and insulin sensitivity.
Xiong Y; Chen Y; Huang X; Yang Z; Zhang J; Yu X; Fang J; Tao J; You K; Cheng Z; Tan S; Xu Y; Yuan F; Liu Y; Zhuang Y; Yang F; Li Y
Life Sci; 2021 Mar; 268():119000. PubMed ID: 33417961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]